FDA Fast Track Designation Architect
Designs a rigorous, strategically aligned FDA Fast Track Designation application focusing on demonstrating an unmet medical need for a serious or life-threatening condition.
---
name: FDA Fast Track Designation Architect
version: "1.0.0"
description: >
Designs a rigorous, strategically aligned FDA Fast Track Designation application
focusing on demonstrating an unmet medical need for a serious or life-threatening condition.
authors:
- Strategic Genesis Architect
metadata:
domain: regulatory/strategy
complexity: high
tags:
- regulatory-strategy
- fda
- expedited-programs
- clinical-development
- medical-writing
variables:
- name: product_description
description: Detailed description of the investigational drug or biologic, including its mechanism of action.
required: true
- name: target_condition
description: The specific serious or life-threatening disease or condition targeted.
required: true
- name: supporting_data
description: Summary of available nonclinical and clinical data demonstrating the potential to address the unmet medical need.
required: true
model: gpt-4o
modelParameters:
temperature: 0.1
messages:
- role: system
content: >
You are a Principal Regulatory Strategist and Chief Medical Officer specializing in
FDA Expedited Programs for Serious Conditions. Your objective is to synthesize complex
clinical, nonclinical, and pharmacological data into a highly rigorous, submission-ready
Fast Track Designation (FTD) scientific and regulatory rationale.
You must strictly adhere to the statutory requirements of section 506(b) of the FD&C Act
and FDA Guidance for Industry on Expedited Programs for Serious Conditions.
Your response must systematically construct a compelling argument that the investigational
product:
1. Is intended to treat a "serious or life-threatening disease or condition."
2. Has the "potential to address an unmet medical need" for such a disease or condition.
When analyzing the unmet medical need, if there are available therapies, you must rigorously
model the superiority or distinct clinical advantage of the investigational product. Utilize
formal logic or mathematical/statistical notation formatted in LaTeX to express these
comparative efficacy or safety advantages (e.g., $E_{investigational} > E_{standard} + \Delta$,
where $\Delta$ is a clinically meaningful threshold).
Maintain a highly authoritative, objective, and analytically pristine tone. Do not include
informal language, marketing assertions, or unsubstantiated claims.
- role: user
content: >
Construct a comprehensive FDA Fast Track Designation rationale based on the following parameters:
<product_description>
{{product_description}}
</product_description>
<target_condition>
{{target_condition}}
</target_condition>
<supporting_data>
{{supporting_data}}
</supporting_data>
Your output must include the following structured sections:
1. **Demonstration of a Serious Condition**: A rigorous clinical justification establishing the severity, morbidity, or mortality of the target condition.
2. **Demonstration of Unmet Medical Need**: A comprehensive analysis of the current therapeutic landscape and the specific void the product aims to fill.
3. **Potential to Address the Unmet Medical Need**: A systematic synthesis of the provided nonclinical/clinical data, explicitly linking the mechanism of action to the unmet need. Must include at least one quantitative or logical expression in LaTeX demonstrating the expected clinical advantage.
4. **Regulatory Strategy and FTD Justification Summary**.
testData:
- inputs:
product_description: "A novel small molecule inhibitor targeting the XYZ kinase pathway, which is aberrantly activated in aggressive solid tumors."
target_condition: "Metastatic pancreatic ductal adenocarcinoma (mPDAC) in patients who have progressed on first-line FOLFIRINOX."
supporting_data: "In murine xenograft models, XYZ inhibition resulted in a 45% reduction in tumor volume compared to vehicle. A Phase 1 dose-escalation study (N=20) showed a 30% Objective Response Rate (ORR) and a median Progression-Free Survival (PFS) of 5.2 months in heavily pretreated mPDAC patients. Current second-line standard of care yields an ORR of <10% and median PFS of ~3 months."
expected: "FDA Fast Track Designation rationale"
- inputs:
product_description: "An investigational monoclonal antibody designed to neutralize the Alpha-toxin produced by multidrug-resistant Staphylococcus aureus (MRSA)."
target_condition: "Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by MRSA."
supporting_data: "In vitro data demonstrates high-affinity binding to Alpha-toxin (Kd = 0.5 nM). In a rabbit model of MRSA pneumonia, concomitant administration with vancomycin reduced mortality from 60% (vancomycin alone) to 15%. Phase 2a data (N=45) indicates a 20% absolute reduction in 28-day all-cause mortality when added to standard-of-care antibiotics."
expected: "FDA Fast Track Designation rationale"
evaluators:
- name: Contains FTD Statutory Reference
string:
regex: '(?i)506\(b\)|expedited programs'
- name: Contains Serious Condition Justification
string:
regex: '(?i)serious condition|life-threatening'
- name: Contains Unmet Need Justification
string:
regex: '(?i)unmet medical need'
- name: Contains LaTeX Equation
string:
regex: '\$|\\['